drugset
drugset / Trial / NCT03801434

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

NCT03801434 ↗

Phase 2 Recruiting 10 enrolled William Shomali Incyte Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.

Timeline

Start
2019-11-15
Primary completion
2028-12-30
Completion
2028-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruxolitinib Small molecule — Oral

Indications

chronic eosinophilic leukemia hypereosinophilic syndrome myeloid/lymphoid neoplasm associated with JAK2 rearrangement splenic disorder